Skip to main content
. 2012 Mar 31;10(1):9–16. doi: 10.4321/s1886-36552012000100003

Table 3.

Interacting drugs prescribed concomitantly with warfarin.

Cases (% of patients) Concomitant drug
(% of interactions)
Potential adverse effects Mechanism of interaction
986
(14)
NSAID
(24)
Excessive gastrointestinal bleeding in individual patients Alteration of gastrointestinal mucosa and platelet agregation8,15,46,47
671
(9)
Simvastatin
(16)
Potentiation of the anticoagulant effect of warfarin. Interaction has been clinically insignificant in the majority of patients. Alteration of warfarin metabolism; inhibition of CYP3A4 isoenzyme8,15,31,39
476
(7)
Amiodarone
(12)
Potentiation of the anticoagulant effect of warfarin. Interaction occurs in the majority of patients, develops within two weeks, and lasts for a prolonged period. Alteration of warfarin metabolism; inhibition of CYP isoenzymes8,15,32,33,39,42,43
338
(5)
Propafenone
(8%)
Potentiation of the anticoagulant effect of warfarin Alteration of warfarin metabolism; inhibition of CYP isoenzymes15,34
310
(4)
Allopurinol
(8)
Potentiation of the anticoagulant effect of warfarin. Bleeding was described in individual patients. Alteration of warfarin elimination35
306
(4)
Amitriptyline
(7)
The anticoagulant effect of warfarin can both increase and decrease. Alteration of warfarin metabolism or slow gastrointestinal motility, thereby modulate warfarin absorbtion45
268
(4)
Levothyroxine
(7)
Potentiation of the anticoagulant effect of warfarin Alteration of vitamin K metabolism15,36
210
(3)
Tramadol
(5)
Potentiation of the anticoagulant effect of warfarin Interaction may be related to the CYP2D6 activity48.49
178
(3)
Amoxicillin
(4)
Potentiation of the anticoagulant effect of warfarin Supression of gut microflora, reduced synthesis of vitamin K-dependent clothing factors8,15,50
120
(2)
Etoricoxib, Celecoxib
(3)
Gastrointestinal bleeding in individual patients Possible pharmacokinetic interaction in people with lower CYP2C9 metabolism; displacement of warfarin from protein binding site51,52
75
(1)
Carbamazepine
(2)
Decrease of the anticoagulant effect of warfarin in individual patients Induction of CYP isoenzymes39,44
65
(<1)
Norfloxacin, Ciprofloacin
(2)
The anticoagulant effect of warfarin may be unexpectedly potentiated and result in bleeding. Uncertain- may be supression of vitamin K production53
48
(<1)
Fluconazole, Itraconazole
(1)
The effects of warfarin may be potentiated in individual patients. Inhibition of CYP isoenzymes15,54
26
(<1)
Cefuroxime
(<1)
Increased risk of hypoprothrombinaemia and increased risk of bleeding. Concomitant administration with warfarin is contraindicated. Vitamin K antagonism, platelet inhibition, decreasing the gut microflora15,55,56
15
(<1)
Azathioprine
(<1)
Inhibition of the anticoagulant effect of warfarin Mechanism is unknown- may decrease the anticoagulant response to warfarin57
10
(<1)
Acetaminophen
(<1)
The anticoagulant effect may be potentiated with high doses of paracetamol or in case of prolonged use. Inhibition of enzymes in vitamin K cycle58,59
5
(<1)
Testosterone
(<1)
Potentiation of the anticoagulant effect of warfarin. Bleeding might occur. Mechanism is not understood. Androgens may increase destruction of clotting factors60
4
(<1)
Metronidazole
(<1)
Potentiation of the anticoagulant effect of warfarin. Bleeding might occur. Inhibition of CYP2C9 isoenzyme15,61
3
(<1)
Fenofibrate
(<1)
Potentiation of the anticoagulant effect of warfarin. Bleeding might occur. Fatalities have been reported. Mechanism is uncertain, displacement of warfarin from binding sites, inhibition of CYP2C9 izoenzyme15,62
2
(<1)
Ciprofibrate
(<1)
Potentiation of the anticoagulant effect of warfarin. Bleeding might occur. Mechanism is uncertain, displacement of warfarin from binding sites, inhibition of CYP2C9 izoenzyme15,63
2
(<1)
Norgestimate
(<1)
Decrease of the anticoagulant effect of warfarin in individual patients Mechanism not understood64